Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Myeloid 1Classical hematology 1

Conditions

Recurrence 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine 10Cyclophosphamide 8fludarabine phosphate 7Whole-Body Irradiation 7Tacrolimus 5Mycophenolic Acid 5Melphalan 5Thiotepa 4Peripheral Blood Stem Cell Transplantation 4Busulfan 4AP 1903 reagent 4thymoglobulin 3Sirolimus 3Cord Blood Stem Cell Transplantation 3Alemtuzumab 3Stem Cell Transplantation 2Specimen Handling 2Rituximab 2Platelet Transfusion 2Meropenem 2Cyclosporine 2Biopsy 2Antilymphocyte Serum 2visilizumab 1venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × darinaparsin × Classical hematology × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡